Literature DB >> 27106262

Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity.

Dan Liu1, Lei Cui2, Yuan Wang1, Guifang Yang3, Jing He2, Ruidong Hao2, Chengpeng Fan1, Mengmeng Qu1, Zhepeng Liu1, Min Wang1, Lang Chen1, Hui Li1, Deyin Guo1.   

Abstract

UNLABELLED: Hepatitis B viral infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Although several viral factors have been identified that may increase the risk for HCC development, the molecular mechanisms leading to the transformation of normal hepatocytes into cancer cells remain elusive. In this study, we demonstrated that the intracellular hepatitis B e antigen (HBeAg) and its precore precursors, but not their homologous core protein, could associate with NUMB and thereby impair the stability and transcriptional activity of tumor suppressor p53. HBeAg and its precursors could disrupt p53-NUMB and HDM2-NUMB interactions and tricomplex p53-HDM2-NUMB formation, inhibit the acetylation and translocation of p53 from cytosol to the nucleus, promote HDM2-mediated ubiquitination and degradation of p53, and suppress p53-dependent apoptosis. A xenograft tumorigenicity assay showed that expression of HBeAg and its precursors promoted carcinogenesis in a mouse model. Immunohistochemical analysis of the bioptic liver samples of HCC patients revealed that HBeAg positivity was associated with reduced transcriptional activity of p53. Taken together, the results suggest a role of intracellular HBeAg and its precursors in HCC development.
CONCLUSION: HBeAg and its precursors promote HDM2-mediated degradation and impair transcriptional activity of p53 by interacting with NUMB, consequently contributing to HCC development. (Hepatology 2016;64:390-404).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27106262     DOI: 10.1002/hep.28594

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 2.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

3.  Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction.

Authors:  Yongfa Zheng; Pingpo Ming; Chengliang Zhu; Yu Si; Shilei Xu; Aidong Chen; Jun Wang; Binghong Zhang
Journal:  J Biol Chem       Date:  2019-01-18       Impact factor: 5.157

4.  Inducible Rubicon facilitates viral replication by antagonizing interferon production.

Authors:  Yushun Wan; Wei Cao; Tao Han; Sheng Ren; Jian Feng; TieLong Chen; Jun Wang; Ruth Broering; Mengji Lu; Ying Zhu
Journal:  Cell Mol Immunol       Date:  2017-04-10       Impact factor: 11.530

5.  Plk1 phosphorylation of Numb leads to impaired DNA damage response.

Authors:  C Shao; S-J Chien; E Farah; Z Li; N Ahmad; X Liu
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

6.  Plasma miR-146a predicts serological conversion of hepatitis B e-antigen (HBeAg) in chronic hepatitis B patients treated with nucleotide analogs.

Authors:  Yi Ouyang; Xiaoyu Fu; Shifang Peng; Deming Tan; Lei Fu
Journal:  Ann Transl Med       Date:  2019-09

7.  Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment.

Authors:  Renyong Guo; Hejun Mao; Xiao Hu; Nengneng Zheng; Dong Yan; Jianqin He; Jiezuan Yang
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

8.  Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma.

Authors:  Jiewei Chen; Chuqiang Huang; Keming Chen; Shuman Li; Xinke Zhang; Jun Cheng; Muyan Cai; Yongbo Xiao
Journal:  Onco Targets Ther       Date:  2018-01-19       Impact factor: 4.147

9.  Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.

Authors:  Xiaoke Li; Daqiao Zhou; Xiaoling Chi; Qin Li; Li Wang; Bingjiu Lu; Dewen Mao; Qikai Wu; Xianbo Wang; Mingxiang Zhang; Jingdong Xue; Yong Li; Wei Lu; Jianchun Guo; Feng Jiang; Xinwei Zhang; Zhiguo Li; Xianzhao Yang; Hui Guo; Danan Gan; Liyun He; Lin Luo; Ludan Zhang; Hongbo Du; Yong'an Ye
Journal:  Hepatol Int       Date:  2020-10-30       Impact factor: 6.047

10.  NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.

Authors:  Jianchao Zhang; Ximing Shao; Haiyan Sun; Ke Liu; Zhihao Ding; Juntao Chen; Lijing Fang; Wu Su; Yang Hong; Huashun Li; Hongchang Li
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.